skip to content
Detailed Quote
5i Report
Rating
B+

Review of Tecsys Inc.

JUL 16, 2024 - TCS has demonstrated strong organic growth, and it has a healthy balance sheet and a strong backlog. Its recent results came in below expectations, but long-term demand looks healthy, and its updated guidance helped to support the stock price. It trades at a premium valuation to its peers, but we feel its strength lies in its niche healthcare vertical market, and if it can continue to grow its sales pipeline and expand its margins, that its premium valuation can be justified. We are maintaining our rating of ‘B+’.

Download Report
Company Profile
Interactive Chart
Key Ratios
Earnings
Analyst Recommendations
5i Recent Questions
Q: Hello, from your growth portfolio, what would be your current ranking in order of purchase please?
Read Answer Asked by Liliane on September 30, 2024
Q: Hi 5i team,

What would be your current 5 best (highest conviction) buys in each of the following categories please.
1. small cap
2. mid cap
Hold target is 3-10 years or longer.
I prefer these categories as they seem to have the most torque (in the right environment) albeit also the most risk.


Cheers,
Steve
Read Answer Asked by Stephen on September 25, 2024
Q: Admittedly, I am not a patient investor. I am disenchanted with Boyd and have to believe that either or all of the other equities mentioned above (which I am not fully invested in) should be a better investment for the medium/long term. Could you please comment on this and suggest the equities, in order of growth expectation, I could replace Boyd with.
Thanks,
Read Answer Asked by Claus on September 20, 2024
Insiders
Share Information
News and Media
Looking for more? Sign up for a FREE 14 day trial! No credit card required

We invite you to sign up for a 14 day free trial of 5i Research!
Experience all the benefits and tools we have to offer; stock research, model portfolios, Q&A with our experts, and so much more. Join a community of like-minded investors today!